TrialJournal for immunotherapy of cancer2023

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).

Jun Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.